Immune Monitoring Partnerships Caprion and HistoGeneX joining forces signals a strong demand for integrated immune monitoring and biomarker development capabilities. This presents a sales opportunity to offer Serametrix’s customizable assays and data analysis services as part of broader, globally scalable immune-oncology programs.

Clinical Trial Readiness Serametrix capabilities in rapid assay development and validation across flow cytometry, serum profiling, and proprietary analytics support large-scale clinical trials. Target biotech and pharma with ongoing or planned immuno-oncology trials that require standardized, proven immune monitoring platforms.

MDSC Expertise Experience in analyzing myeloid-derived suppressor cells (MDSC) positions Serametrix to address resistance mechanisms to immune therapies. This can unlock opportunities with sponsors seeking biomarkers for patient stratification and response prediction.

Global Accredited Labs Operations across the Americas, Europe, and China offer global sample handling and compliance capabilities. This is attractive to multinational sponsors needing consistent assay performance and centralized data across trial sites.

Growing Enterprise Post-acquisition by Caprion Biosciences and strategic partnerships indicate a scalable business model with expanding capabilities. Engage with Serametrix for bundled biomarker services, assay development, and data analytics to accelerate drug development timelines.